Yuhan Corporation (KRX:000100)
93,300
-400 (-0.43%)
At close: Apr 29, 2026
Yuhan Revenue
In the year 2025, Yuhan had annual revenue of 2.19T KRW with 5.75% growth. Yuhan had revenue of 546.07B in the quarter ending December 31, 2025, with 10.07% growth.
Revenue
2,186.64B
Revenue Growth
+5.75%
P/S Ratio
3.18
Revenue / Employee
1.06B
Employees
2,067
Market Cap
6,958.57B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2,186.64B | 118.85B | 5.75% |
| Dec 31, 2024 | 2,067.79B | 208.81B | 11.23% |
| Dec 31, 2023 | 1,858.98B | 83.14B | 4.68% |
| Dec 31, 2022 | 1,775.85B | 88.04B | 5.22% |
| Dec 31, 2021 | 1,687.81B | 67.95B | 4.19% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hanmi Pharm. | 1,547.53B |
| Hanall Biopharma | 155.18B |
| Celltrion Pharm | 274.73B |
| Daewoong Pharmaceutical | 1,570.89B |
| GC Biopharma | 1,991.28B |
| Chong Kun Dang Pharmaceutical | 1,692.40B |
| DongKook Pharmaceutical | 926.88B |
| Daewoong | 2,068.37B |